??ICYMI: Sign up to read this EXCLUSIVE roundup of insights from clinicians highlighting data on the top abstracts to come out of #ESMO2024! Read here ?? https://lnkd.in/eAdEgp4C
关于我们
OncLive is the official website for the Intellisphere, LLC Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Oncology Fellows. The mission of OncLive is to arm oncology professionals with the resources and information they need to provide the best patient care. We cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. OncLive allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds, breaking news, and live coverage from major oncology meetings.
- 网站
-
https://onclive.com
OncLive的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 51-200 人
- 总部
- Cranbury，NJ
- 类型
- 私人持股
地点
-
主要
获取路线
2 Clarke Dr
US，NJ，Cranbury，08512
OncLive员工
-
Chandler Park, M.D., F.A.C.P.
Award Winning Oncologist| 3x NEJM Published Author| ASCO Faculty|Advisory Dean/Clinical Professor UofL Medical School|Kentucky Leader ASCO ASH NCCN…
-
Julie Ruff, RDN
National Account Manager | OncLive Medical?| Medical Affairs | Sales
-
Morgan Burum
Director of Sales
-
Gabrielle Gelchion
National Account Manager, Onclive Events?
动态
-
Dive into expert insights on #GastricCancer biomarkers in under 3 mins! Explore the latest in testing and treatment strategies. #GastricCancer #Biomarkers Watch here: https://ow.ly/sk4z50TOBEa
-
-
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy. Society for Immunotherapy of Cancer (SITC) #SITC2024 #oncology #melanoma https://lnkd.in/eH-TsJrZ
-
?? Calling all oncologists! Don't forget that this week from November 13–15, the 42nd Annual CFS is taking place! Listen in as Yan Leyfman, MD, of MedNews Week, provides a special message on the meeting! #CFS24 Learn more & register here https://lnkd.in/ewP6ECwq
-
Hear Lori Wirth, MD of Mass General Brigham, Francis Worden, MD of Rogel Cancer Center, Hyunseok Kang, MD of UCSF Health, Marcia Brose MD, PhD, of Sidney Kimmel Comprehensive Cancer Center at Jefferson and Daniel Bowles, MD of UChicago Medicine discuss epidemiological trends in differentiated #thyroidcancer. Watch here: https://lnkd.in/gaFythFG
-
Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel. Society for Immunotherapy of Cancer (SITC) #SITC2024 #oncology https://lnkd.in/eEMPK_Bv
Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy
onclive.com
-
THIO plus cemiplimab displayed durable activity in patients with advanced checkpoint inhibitor–resistant NSCLC. Society for Immunotherapy of Cancer (SITC) #SITC2024 #oncology #NSCLC https://lnkd.in/e6RDS9Nh
THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC
onclive.com
-
Tanios Bekaii-Saab,MD,?of Mayo Clinic shares insights?about the evolving role of RAS-targeted therapies in #pancreaticcancer and where future research in the field may be headed. https://lnkd.in/gyYdT3Bt
Continued Development of RAS Inhibitors Leads the Charge in Pancreatic Cancer Research
onclive.com
-
BREAKING: The FDA has approved obecabtagene autoleucel (Aucatzyl) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic #leukemia. https://lnkd.in/eSB7pt7m
-
-
Amer Zeidan, MBBS, of Yale School of Medicine discusses luspatercept's superior erythroid response rates and duration of RBC transfusion independence compared with epoetin alfa in lower-risk #MDS. https://lnkd.in/gX-rSuP7
Luspatercept Generates Across-the-Board Benefit for Lower-Risk MDS in COMMANDS
onclive.com